<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03076164</url>
  </required_header>
  <id_info>
    <org_study_id>15-098</org_study_id>
    <nct_id>NCT03076164</nct_id>
  </id_info>
  <brief_title>A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib</brief_title>
  <official_title>A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability and overall response rate
      of trametinib when given in combination with erlotinib in patients with Stage IV or recurrent
      lung adenocarcinoma that cannot be treated with curative intent.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Trametinib 1.5mg + Erlotinib 75mg</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>2 years</time_frame>
    <description>Response and progression of disease will be evaluated in this study using interval imaging every 8 weeks with CT scan of the chest and imaging of any other target lesion with response evaluated by RECIST 1.1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability will be evaluated by systematic and regular toxicity evaluations. Toxicity will be graded according to NCI CTCAE version 4.0.</measure>
    <time_frame>2 years</time_frame>
    <description>Safety and tolerability will be evaluated by systematic and regular toxicity evaluations. Toxicity will be graded according to NCI CTCAE version 4.0.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lung Adenocarcinoma</condition>
  <condition>Lung Cancer</condition>
  <condition>Lung Cancer Metastatic</condition>
  <condition>Lung Cancer Stage IV</condition>
  <condition>Recurrent Lung Adenocarcinoma</condition>
  <condition>Recurrent Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Trametinib 1.5mg + Erlotinib 75mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1: Accrue 6 patients on Trametinib 1.5mg + Erlotinib 75mg by mouth once daily Phase 2: Accrue 24 patients (including 6 patients treated during Phase 1) on Trametinib 1.5mg + Erlotinib 75mg by mouth once daily or Trametinib 1.0mg + Erlotinib 100mg by mouth once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib</intervention_name>
    <description>Trametinib 1.5mg once daily by mouth</description>
    <arm_group_label>Trametinib 1.5mg + Erlotinib 75mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>Erlotinib 75mg once daily by mouth</description>
    <arm_group_label>Trametinib 1.5mg + Erlotinib 75mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologic evidence of advanced stage IV or recurrent lung adenocarcinoma reviewed at
             MSKCC

          -  Somatic activating mutation in EGFR Radiographic progression during treatment with
             erlotinib.

          -  Any number of prior chemotherapy regimens is permitted.

          -  Measurable (RECIST 1.1) indicator lesion not previously irradiated

          -  KPS &gt;/= 70%

          -  Age &gt;18 years old

          -  Must have undergone biopsy after development of acquired resistance to erlotinib with
             available archived tissue (equivalent of &gt; 10 unstained slides)

          -  Left ventricular Ejection Fraction &gt;/= the lower limit of normal by ECHO or MUGA

          -  Adequate organ function:

          -  AST, ALT &lt;/= 2.5 x ULN

          -  Total bilirubin &lt;/= 1.5 x ULN

          -  Albumin&gt;/=2.6g/dL - Creatinine &lt; 1.5 x ULN OR calculated creatinine clearance
             &gt;/=50mL/min

          -  Absolute neutrophil count (ANC) &gt;/= 1,200 cells/mm3

          -  Hemoglobin&gt;/=9.0 g/dL

          -  Platelets &gt;/=100,000/mm3

        Exclusion Criteria:

          -  Patients with symptomatic brain metastasis requiring escalating doses of steroids

          -  Patients with grade 2 or greater diarrhea prior to study initiation despite maximal
             medical management due to medications or a medical condition such as Crohn's disease
             or malabsorption

          -  Pregnant or lactating women

          -  Any type of systemic therapy (chemotherapy or experimental drugs) within 2 weeks of
             starting treatment on protocol except for a EGFR TKI

          -  Patients who have received prior treatment with a MEK inhibitor

          -  Any major surgery or extensive radiotherapy within 21 days of starting treatment on
             protocol.

          -  A history of clinically significant interstitial lung disease or pneumonitis

          -  Clinically significant cardiac disease including unstable angina, acute myocardial
             infarction within 6 months from Day 1 of study administration, New York Heart
             Association Class III or IV congestive heart failure, or symptomatic uncontrolled
             Arrythmias, prolonged corrected QT interval &gt;480msec, treatment refractory
             hypertension, presence of a cardiac defibrillator

          -  History of central serous retinopathy or retinal vein occlusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Helena Yu, MD</last_name>
    <phone>646-888-4274</phone>
    <email>yuh@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gergory Riely, MD, PhD</last_name>
    <phone>646-888-4199</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Yu, MD</last_name>
      <phone>646-888-4274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center @ Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Yu, MD</last_name>
      <phone>646-888-4274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Yu, MD</last_name>
      <phone>646-888-4274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan - Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Yu, MD</last_name>
      <phone>646-888-4274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering @ Rockville</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <zip>11570</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Yu, MD</last_name>
      <phone>646-888-4274</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2017</study_first_submitted>
  <study_first_submitted_qc>March 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2017</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>erlotinib</keyword>
  <keyword>trametinib</keyword>
  <keyword>15-098</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

